Eleven Biotherapeutics Inc. (NASDAQ:EBIO) dropped 6.2% on Monday . The stock traded as low as $3.41 and last traded at $3.47, with a volume of 493,653 shares traded. The stock had previously closed at $3.70.

The firm’s market capitalization is $51.87 million. The firm has a 50 day moving average of $4.45 and a 200-day moving average of $2.18.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. On average, equities analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.

In other Eleven Biotherapeutics news, major shareholder Ventures Fund 2007 L. Flagship sold 46,692 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $4.18, for a total transaction of $195,172.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ventures Fund 2007 L. Flagship sold 129,497 shares of the company’s stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $4.54, for a total value of $587,916.38. The disclosure for this sale can be found here. Company insiders own 28.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Flagship Ventures Fund 2007 L.P. purchased a new stake in shares of Eleven Biotherapeutics during the first quarter valued at approximately $610,000. Flagship Ventures Fund IV L.P. purchased a new stake in shares of Eleven Biotherapeutics during the first quarter valued at approximately $469,000. Flagship Ventures Fund IV General Partner LLC purchased a new stake in shares of Eleven Biotherapeutics during the second quarter valued at approximately $2,464,000. Sabby Management LLC raised its stake in shares of Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares in the last quarter. Finally, Boxer Capital LLC purchased a new stake in shares of Eleven Biotherapeutics during the second quarter valued at approximately $1,670,000. Institutional investors own 24.81% of the company’s stock.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.

5 Day Chart for NASDAQ:EBIO

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.